New global registry tracks safety of common blood thinners in APS patients
Knowledge-focused
Recruiting now
This study is creating a global registry of 500 adults with antiphospholipid syndrome (APS) who are taking direct oral anticoagulants (DOACs) like rivaroxaban or apixaban. Researchers will track rates of recurrent blood clots and bleeding over at least 6 months. The goal is to ga…
Sponsor: Stéphane Zuily • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC